Graded doses of recombinant interleukin-1β induce generalized osteopenia in rats without altering skeletal growth and joint integrity

Hormone Research

Volumn 64, Issue 2, 2005, Pages 88-95

  Del Pozo, E ^a   Popp, A W E ^a   MacKenzie, A ^b   Perrelet, R ^a   Lamberts, S W J ^c   Lippuner, K ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Bone mineral content; Bone turnover; Interleukin 1 ; Skeletal growth

Indexed keywords

RECOMBINANT INTERLEUKIN 1BETA;

ABSORPTIOMETRY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE GROWTH; CALCIUM TRANSPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; FEMALE; NONHUMAN; OSMOTIC PUMP; OSTEOPENIA; PRIORITY JOURNAL; RAT; TRABECULAR BONE; X RAY ANALYSIS;

ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DEVELOPMENT; BONE DISEASES, METABOLIC; CALCIUM; CARTILAGE, ARTICULAR; CORTICOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOOT; INTERLEUKIN-1; JOINTS; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; WEIGHT GAIN;

EID: 26444445214     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088169     Document Type: Article

References (48)

1. Martel W, Holt JF, Cassidy JT: Roentgenology manifestations of juvenile rheumatoid arthritis. Am J Roentgenol 1962;88:400-423.
2. Cassidy JT, Brody GL, Martel W: Monarticular juvenile rheumatoid arthritis. J Pediatr 1967;70:867-875.
3. Ansell BM, Kent P: Radiological changes in juvenile chronic polyarthritis. Skeletal Radiol 1977;1:129-144.
4. Als OS, Gotfredson A, Christiansen C: The effect of glucocorticoids on bone mass in rheumatoid arthritis patients. Arthritis Rheum 1985;28:369-375.
5. Sambrook PN, Eisman JA, Champion GD, Yeates MG, Pocock NA, Ebel S: Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum 1987;30:721-728.
6. Gough AKS, Lilley J, Eyre S, Holder RL, Emery P: Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994;344:23-27.
7. White PH: Growth abnormalities in children with juvenile rheumatoid arthritis. Clin Orthop Rel Res 1990;259:46-50.
8. Bernstein BH, Stoble D, Singsen BH: Growth retardation in juvenile rheumatoid arthritis. Arthritis Rheum 1977;20:212-216.
9. Ghivizzani SC, Kang R, Georgescu HI, Lechman ER, Jaffurs D, Engle JM, Watkins SC, Tindal MH, Suchanek MK, McKenzie LR, Evans CH, Robbins PD: Constitutive intra-articular expression of human IL-1 beta following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis. J Immunol 1997;159:3604-3612.
10. Van den Berg WB, van der Kraan PM, Scharstuhl A, van Beuningen HM: Growth factors and cartilage repair. Clin Orthop 2001(391 suppl):S244-250.
11. Bernton EW, Beach JE, Holaday JW, Smallridge RC, Fein HG: Release of multiple hormones by a direct action of interleukin-1 on pituitary cells. Science 1987;238:519-521.
12. Beach JE, Smallridge RC, Kinzer CA, Bernton EW, Holaday JW, Fein HG: Rapid release of multiple hormones from fat pituitaries perifused with recombinant interleukin-1. Life Sci 1989;44:1-7.
13. Honegger J, Spagnoli A, D'Urso R, Navarra P, Tsagarakis S, Besser GM, Grossman AB: Interleukin-1β modulates the acute release of growth hormone-releasing hormone and somatostatin from rat hypothalamus in vitro, whereas tumor necrosis factor and interleukin-6 have no effect. Endocrinology 1991;129:1275-1282.
14. Wada Y, Sato M, Niimi M, Tamaki M, Ishida T, Takahara J: Inhibitory effects of interleukin-1 on growth hormone secretion in conscious male rats. Endocrinology 1995;136:3936-3941.
15. Fan J, Wojnar M, Theodorakis M, Lang CH: Regulation of insulin-like growth factor (IGF-1) mRNA and peptide and IGF-binding proteins by interleukin-1. Am J Physiol 1996;270:R621-R629.
16. Wolf M, Böhm S, Brand M, Kreymann G: Proinflammatory cytokines interleukin 1β and tumor necrosis factor alpha inhibit growth hormone stimulation of insulin-like growth factor 1 synthesis and growth hormone receptor mRNA levels in cultured rat liver cells. Eur J Endocrinol 1996;135:729-737.
17. Moerenhout M: The Effect of Graded Doses of Recombinant Interleukin-1β on Bone Remodelling in Growing Rats; thesis, University of Louvain, 1992.
18. Sweep CGJ, van Der Meer MJM, Hermus RMM, Smals AGH, van Der Meer JWM, Pesman J, Willemsen SJ, Benraad TJ, Kloppenborg PWC: Chronic stimulation of the pituitary-adrenal axis in rats by interleukin-1β infusions: in vivo and in vitro studies. Endocrinology 1992;130:1153-1164.
19. Sabatini M, Boyce B, Aufdemorte T, Bonewald L, Mundy GR: Infusions of recombinant human interleukins 1α and 1β cause hypercalcemia in normal mice. Proc Natl Acad Sci USA 1988;85:5235-5239.
20. Boyce B, Aufdemorte TB, Ross Garrett I, Yates AJP, Mundy GR: Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 1989;125:1142-1150.
21. Nguyen L, Dewhirst FE, Hauschka PV, Stashenko P: Interleukin-1β stimulates bone resorption and inhibits bone formation in vivo. Lymphokine Cytokine Res 1991;10:15-21.
22. Casez JP, Muelbauer RC, Lippuner K, Kelly T, Fleisch H, Jaeger PH: Dual-energy X-ray absorptiometry for measuring total bone mineral content in the rat: study of accuracy and precision. Bone Miner 1994;26:61-68.
23. Modrowsky D, del Pozo E, Miravet L: Dynamics of circulating osteocalcin in rats during growth and under experimental conditions. Horm Metab Res 1992;24:474-477.
24. del Pozo E, Perrelet R, Tschaggelar D, Marbach P, Lamberts SWJ: Control of growth hormone secretion: experimental data and clinical correlates; in Gupta D, Wollmann HA, Ranke MB (eds): Neuroendocrinology: New Frontiers. London, Brain Research Promotion, 1990, pp 417-430.
25. del Pozo E, Zapf J: Skeletal growth and bone density as sensitive parameters in experimental arthritis: effect of cyclosporin A. Bone 1994;15:625-628.
26. Furlanetto RW, Underwood LE, van Wyk JJ, D'Ercole AJ: Estimation of somatomedin levels in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest 1977;60:648-657.
27. Ross Garrett I, Mundy GR: Relationship between interleukin-1 and prostaglandins in resorbing neonatal calvaria. J Bone Miner Res 1989;4:789-794.
28. Stashenko P, Dewhirst FE, Rooney ML, Desjardins LA, Heeley JD: Interleukin-1β is a potent inhibitor of bone formation in vitro. J Bone Miner Res 1987;2:559-565.
29. Taichman RS, Hauschka PV: Effects of interleukin-1 beta and tumor necrosis factor-alpha on osteoblastic expression of osteocalcin and mineralized extracellular matrix in vitro. Inflammation 1992;16:587-601.
30. Evans DB, Bunning RA, Russell RG: The effects of recombinant human interleukin-1 beta on cellular proliferation and the production of prostaglandin E2, plasminogen activator, osteocalcin and alkaline phosphatase by osteoblast-like cells derived from human bone. Biochem Biophys Res Commun 1990;166:208-216.
31. Kimble RB, Vannice JL, Bloedow DC, Thompson RC, Hopfer W, Brownfield C, Pacifici R: Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest 1994;93:1959-1967.
32. Rosenquist JB, Ohlin A, Lerner UH: Cytokine-induced inhibition of bone matrix proteins is not mediated by prostaglandins. Inflamm Res 1996;45:457-463.
33. Pettipher ER, Higgs GA, Henderson B: Interleukin-1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci USA 1986;83:8749-8753.
34. Van de Loo AA, van den Berg WB: Effects of murine recombinant interleukin 1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis 1990;49:238-245.
35. Cooper C, Fall C, Egger P, Hobbs R, Eastell R, Barker D: Growth in infancy and bone mass in later life. Ann Rheum Dis 1997;56:17-21.
36. Gale CR, Martyn CN, Kellingray S, Eastell R, Cooper C: Intrauterine programming of adult body composition. J Clin Endocrinol Metab 2001;86:267-272.
37. Swolin-Eide D, Nilsson C, Holmäng A, Ohlsson C: Prenatal exposure to IL-1β results in disturbed skeletal growth in adult rat offspring. Pediatr Res 2004;55:1-6.
38. Mårtensson K, Chrysis D, Sävendahl L: Interleukin-1β and TNF-α act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones. J Bone Miner Res 2004;19:1805-1812.
39. Peisen JN, McDonnell KJ, Mulroney SE, Lumpkin MD: Endotoxin-induced suppression of the somatotropic axis is mediated by interleukin-1β and corticotropin-releasing factor in the juvenile rat. Endocrinology 1995;136:3378-3390.
40. Corsi MM, Fulgenzi A, Gaja G, Falchi M, Bertelli AA, Boctelli AA, Ferrero ME: Effect of acute and chronic inflammation on plasma growth hormone levels in rats. Drugs Exp Clin Res 1997;23:117-122.
41. Thissen JP, Verniers J: Inhibition by interleukin-1 beta and tumor necrosis factor-alpha of the insulin-like growth factor 1 messenger ribonucleic acid response to growth hormone in rat hepatocyte primary culture. Endocrinology 1997;138:1078-1084.
42. Lippuner K, del Pozo E, MacKenzie A, Jaeger P: Long-term systemic administration of human recombinant interleukin-1β induces a dose-dependent fall in circulating parathyroid hormone in rats. Horm Res 1999;51:74-77.
43. Spencer EM, Si EC, Liu CC, Howard GA: Parathyroid hormone potentiates the effect of insulin-like growth factor-I on bone formation. Acta Endocrinol (Copenh) 1989;121:435-442.
44. del Pozo E, Elford P, Perrelet R, Graeber M, Casez JP, Modrowski D, Payne T, MacKenzie AR: Prevention of adjuvant arthritis by cyclosporine in rats. Semin Arthritis Rheum 1992;21(suppl 3):23-29.
45. Ibañez de Caceres I, Villanua MA, Soto L, Martin AI, Lopez-Calderon A: IGF-I and IGF-I-binding proteins in rats with adjuvant-induced arthritis given recombinant human growth hormone. J Endocrinol 2000;165:537-544.
46. Soto L, Martin AI, Vara E, Lopez-Calderon A: Cyclosporin A treatment is able to revert the decrease in circulating GH and IGF-I and the increase in IGFBPs induced by adjuvant arthritis. Horm Metab Res 2001;33:590-595.
47. Butler LD, Layman NK, Cain RL, Riedl PE, Mohler KM, Bobbitt JL, Belagajie R, Sharp J, Bendele AM: Interleukin 1-induced pathophysiology: induction of cytokines, development of histopathologic changes, and immunopharmacologic intervention. Clin Immunol Immunopathol 1989;53:400-421.
48. Rifas L: Bone and cytokines: beyond IL-1, IL-6 and TNF-α. Calcif Tissue Int 1999;64:1-7.